Bimekizumab demonstrated sustained response in hidradenitis suppurativa (HS), according to a late breaker presented at Maui Derm 2024.
Almost all patients who responded after an initial 16 weeks of bimekizumab treatment maintained HiSCR50 (Hidradenitis Suppurativa Clinical Response) and AN count of 0, 1, or 2 clinical response rates through Wk48, the study showed.
Bimekizumab, a humanized IgG1 monoclonal antibody that selectively inhibits interleukin (IL)-17F and IL-17A, has previously demonstrated efficacy in patients with moderate to severe HS at phase 2.
For the study, researchers pooled data from randomized, double-blind, placebo-controlled, BE HEARD I and II trials. The trials included an initial (Wks 0–16) and a maintenance treatment period (Wks 16–48). Adult patients were randomized 2:2:2:1 (initial/maintenance) to receive:
• Bimekizumab 320mg every 2 wks (Q2W)/Q2W
• Bimekizumab Q2W/every 4 wks (Q4W)
• Bimekizumab Q4W/Q4W
• Placebo/bimekizumab Q2W
Maintenance of response is reported as the percentage of Bimekizumab-treated patients who achieved 50% HS Clinical Response.
At baseline, 1,014 patients were randomized to placebo/bimekizumab Q2W (n=146), Bimekizumab Q4W/Q4W (n=288), bimekizumab Q2W/Q4W (n=292) or bimekizumab Q2W/Q2W (n=288).
Among Wk16 HiSCR50 responders in the bimekizumab Q4W/Q4W (n=152), bimekizumab Q2W/Q4W (n=155) and bimekizumab Q2W/Q2W (n=160) groups, 89.6% (103/115), 88.5% (116/131) and 88.8% (111/125) maintained response through Wk48, respectively.
Patients with an AN count of 0, 1, or 2 at Wk16 in the bimekizumab Q4W/Q4W (n=87), Bimekizumab Q2W/Q4W (n=99) and bimekizumab Q2W/Q2W (n=104) groups, 86.4% (57/66), 88.0% (73/83) and 82.1% (69/84) maintained response through Wk48, respectively, the study showed.
